Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × poly(I).poly(c12,U) × Clear all

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

Triple Negative Breast Neoplasms